For example, non-small cell lung cancer (NSCLC) regimens are organized by EGFR, ALK, BRAF, and ROS1 mutation status; kinase inhibitors are categorized by their target kinase(s) and biomarker-specific FDA labeling is noted. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.